Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Mike M who wrote (1673)	11/29/1999 10:08:00 PM
From: Bo Didley	Read Replies (1) \| Respond to of 5582

My 4Q estimates Clearly the wild card is the increase of production beginning mid-Dec to 300,000 units/week Without the wild card and using a simple production at 180,000/units per week.... (btw: it costs $1.45/unit to produce) ^keeping the gum business the same as Q3 ^2M in advertising ^Citadel payments --- I think their plan was to increase payments to get them paid off quickly. For each additional million Zicam sold, add $700k to the sales. This is where the last 15 days of December will be the wild card, and how those sales are booked. Dan, have you covered how Zicam sales are booked? That maybe a good thing for the website. My guestimate...still working on it but one thing is clear, GUMM is going to be profitable, and more importantly, beginning Q1, they start their entire FUTURE year off profitable. In Q4 release, I hope they give us a hint of how they are doing for Q1. Only us pseudo-analysts cover GUMM so investors really have no projection to meet. I'm inclined for numbers under 20c/share. New Investors can read the basics of GUMM at a newly created website: gumminvestors.com bo